Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Biotechnology 26, 954 (1 September 2008) | doi:10.1038/nbt0908-954
This means war
Abstract
Take two biotech start-ups with precisely the same preclinical cancer portfolio at exactly the same time. Put one in Europe and take the other to the United States.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
